Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Michael Bristow to Heart

This is a "connection" page, showing publications Michael Bristow has written about Heart.

 
Connection Strength
  
 
 
2.049
  
  1. Calalb MB, McKinsey TA, Newkirk S, Huynh K, Sucharov CC, Bristow MR. Increased phosphorylation-dependent nuclear export of class II histone deacetylases in failing human heart. Clin Transl Sci. 2009 Oct; 2(5):325-32.
    View in: PubMed
    Score: 0.239
  2. Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol. 1997 Dec 04; 80(11A):26L-40L.
    View in: PubMed
    Score: 0.105
  3. Leary PJ, Bristow MR. Reply: Is Histamine H2 Receptor a Real Promising Target for Prevention or Treatment of Heart Failure? J Am Coll Cardiol. 2016 11 01; 68(18):2029-2030.
    View in: PubMed
    Score: 0.098
  4. Yoshikawa T, Port JD, Asano K, Chidiak P, Bouvier M, Dutcher D, Roden RL, Minobe W, Tremmel KD, Bristow MR. Cardiac adrenergic receptor effects of carvedilol. Eur Heart J. 1996 Apr; 17 Suppl B:8-16.
    View in: PubMed
    Score: 0.094
  5. Focaccio A, Peeters G, Movsesian M, Roden R, Eki Y, Krall J, Bristow MR. Mechanism of action of OPC-8490 in human ventricular myocardium. Circulation. 1996 Feb 15; 93(4):817-25.
    View in: PubMed
    Score: 0.093
  6. Abraham WT, Lowes BD, White M, Ferguson DA, Scheffel CA, Wolfel EE, Lindenfeld J, Bristow MR. Comparative hemodynamic effects of OPC-18790 and dobutamine in patients with advanced heart failure. J Card Fail. 1994 Oct; 1(1):57-62.
    View in: PubMed
    Score: 0.085
  7. Bristow MR. Changes in myocardial and vascular receptors in heart failure. J Am Coll Cardiol. 1993 Oct; 22(4 Suppl A):61A-71A.
    View in: PubMed
    Score: 0.079
  8. Bristow MR, Minobe W, Rasmussen R, Larrabee P, Skerl L, Klein JW, Anderson FL, Murray J, Mestroni L, Karwande SV, et al. Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J Clin Invest. 1992 Mar; 89(3):803-15.
    View in: PubMed
    Score: 0.071
  9. Bristow MR, Feldman AM. Changes in the receptor-G protein-adenylyl cyclase system in heart failure from various types of heart muscle disease. Basic Res Cardiol. 1992; 87 Suppl 1:15-35.
    View in: PubMed
    Score: 0.070
  10. Bristow MR, Anderson FL, Port JD, Skerl L, Hershberger RE, Larrabee P, O'Connell JB, Renlund DG, Volkman K, Murray J, et al. Differences in beta-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. Circulation. 1991 Sep; 84(3):1024-39.
    View in: PubMed
    Score: 0.068
  11. Hershberger RE, Feldman AM, Anderson FL, Kimball JA, Wynn JR, Bristow MR. Mr 40,000 and Mr 39,000 pertussis toxin substrates are increased in surgically denervated dog ventricular myocardium. J Cardiovasc Pharmacol. 1991 Apr; 17(4):568-75.
    View in: PubMed
    Score: 0.066
  12. Bristow MR, Hershberger RE, Port JD, Gilbert EM, Sandoval A, Rasmussen R, Cates AE, Feldman AM. Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation. 1990 Aug; 82(2 Suppl):I12-25.
    View in: PubMed
    Score: 0.063
  13. Hershberger RE, Wynn JR, Sundberg L, Bristow MR. Mechanism of action of bucindolol in human ventricular myocardium. J Cardiovasc Pharmacol. 1990 Jun; 15(6):959-67.
    View in: PubMed
    Score: 0.063
  14. Feldman AM, Bristow MR. The beta-adrenergic pathway in the failing human heart: implications for inotropic therapy. Cardiology. 1990; 77 Suppl 1:1-32.
    View in: PubMed
    Score: 0.061
  15. Kline KG, Frewen B, Bristow MR, Maccoss MJ, Wu CC. High quality catalog of proteotypic peptides from human heart. J Proteome Res. 2008 Nov; 7(11):5055-61.
    View in: PubMed
    Score: 0.056
  16. Anderson FL, Kralios AC, Hershberger R, Bristow MR. Desensitization of myocardial but not coronary VIP receptor-mediated responses in dogs. Am J Physiol. 1988 Sep; 255(3 Pt 2):H601-7.
    View in: PubMed
    Score: 0.055
  17. Bristow MR. The beta-adrenergic receptor. Configuration, regulation, mechanism of action. Postgrad Med. 1988 Feb 29; Spec No:19-26.
    View in: PubMed
    Score: 0.054
  18. Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow MR. Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation. 1986 Dec; 74(6):1290-302.
    View in: PubMed
    Score: 0.049
  19. Bristow MR. Cardiac resynchronization therapy and adrenergic mechanisms. Am J Physiol Heart Circ Physiol. 2006 Dec; 291(6):H2590-1.
    View in: PubMed
    Score: 0.048
  20. Feldman DS, Carnes CA, Abraham WT, Bristow MR. Mechanisms of disease: beta-adrenergic receptors--alterations in signal transduction and pharmacogenomics in heart failure. Nat Clin Pract Cardiovasc Med. 2005 Sep; 2(9):475-83.
    View in: PubMed
    Score: 0.045
  21. Kantrowitz NE, Bristow MR. Cardiotoxicity of antitumor agents. Prog Cardiovasc Dis. 1984 Nov-Dec; 27(3):195-200.
    View in: PubMed
    Score: 0.043
  22. Bristow MR, Ginsburg R, Strosberg A, Montgomery W, Minobe W. Pharmacology and inotropic potential of forskolin in the human heart. J Clin Invest. 1984 Jul; 74(1):212-23.
    View in: PubMed
    Score: 0.042
  23. Zhao Y, Riching AS, Knight WE, Chi C, Broadwell LJ, Du Y, Abdel-Hafiz M, Ambardekar AV, Irwin DC, Proenza C, Xu H, Leinwand LA, Walker LA, Woulfe KC, Bristow MR, Buttrick PM, Song K. Cardiomyocyte-Specific Long Noncoding RNA Regulates Alternative Splicing of the Triadin Gene in the Heart. Circulation. 2022 08 30; 146(9):699-714.
    View in: PubMed
    Score: 0.036
  24. Bristow MR, Ginsburg R, Harrison DC. Histamine and the human heart: the other receptor system. Am J Cardiol. 1982 Jan; 49(1):249-51.
    View in: PubMed
    Score: 0.035
  25. Hailu FT, Karimpour-Fard A, Toni LS, Bristow MR, Miyamoto SD, Stauffer BL, Sucharov CC. Integrated analysis of miRNA-mRNA interaction in pediatric dilated cardiomyopathy. Pediatr Res. 2022 07; 92(1):98-108.
    View in: PubMed
    Score: 0.033
  26. Bisognano JD, Weinberger HD, Bohlmeyer TJ, Pende A, Raynolds MV, Sastravaha A, Roden R, Asano K, Blaxall BC, Wu SC, Communal C, Singh K, Colucci W, Bristow MR, Port DJ. Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice. J Mol Cell Cardiol. 2000 May; 32(5):817-30.
    View in: PubMed
    Score: 0.031
  27. Bristow MR. Testing for doxorubicin cardiotoxicity. N Engl J Med. 1979 Jun 14; 300(24):1393.
    View in: PubMed
    Score: 0.029
  28. Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Harrison DC. Early anthracycline cardiotoxicity. Am J Med. 1978 Nov; 65(5):823-32.
    View in: PubMed
    Score: 0.028
  29. Bristow MR, Mason JW, Billingham ME, Daniels JR. Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med. 1978 Feb; 88(2):168-75.
    View in: PubMed
    Score: 0.027
  30. Bristow MR, Daniels JR, Kernoff RS, Harrison DC. Effect of D600, practolol, and alterations in magnesium on ionized calcium concentration-response relationships in the intact dog heart. Circ Res. 1977 Oct; 41(4):574-81.
    View in: PubMed
    Score: 0.026
  31. Deisher TA, Ginsburg R, Fowler MB, Billingham ME, Bristow MR. Spontaneous reversibility of catecholamine-induced cardiotoxicity in rats. Am J Cardiovasc Pathol. 1995; 5(1):79-88.
    View in: PubMed
    Score: 0.022
  32. Anderson FL, Port JD, Reid BB, Hanson G, Kralios AC, Hershberger RE, Bristow MR. Effect of therapeutic dopamine administration on myocardial catecholamine and neuropeptide Y concentrations in the failing ventricles of patients with idiopathic dilated cardiomyopathy. J Cardiovasc Pharmacol. 1992; 20(5):800-6.
    View in: PubMed
    Score: 0.017
  33. Bristow M. Vasodilation in treatment of hypertension. N Engl J Med. 1970 May 07; 282(19):1102.
    View in: PubMed
    Score: 0.016
  34. Bristow MR, Sandoval AB, Gilbert EM, Deisher T, Minobe W, Rasmussen R. Myocardial alpha- and beta-adrenergic receptors in heart failure: is cardiac-derived norepinephrine the regulatory signal? Eur Heart J. 1988 Jun; 9 Suppl H:35-40.
    View in: PubMed
    Score: 0.014
  35. Bristow MR, Ginsburg R. Beta 2 receptors on myocardial cells in human ventricular myocardium. Am J Cardiol. 1986 Apr 25; 57(12):3F-6F.
    View in: PubMed
    Score: 0.012
  36. McKillop JH, Bristow MR, Goris ML, Billingham ME, Bockemuehl K. Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am Heart J. 1983 Nov; 106(5 Pt 1):1048-56.
    View in: PubMed
    Score: 0.010
  37. Ginsburg R, Esserman LJ, Bristow MR. Myocardial performance and extracellular ionized calcium in a severely failing human heart. Ann Intern Med. 1983 May; 98(5 Pt 1):603-6.
    View in: PubMed
    Score: 0.010
  38. Bristow MR. Toxic cardiomyopathy due to doxorubicin. Hosp Pract (Off Ed). 1982 Dec; 17(12):101-8, 110-1.
    View in: PubMed
    Score: 0.009
  39. Bristow MR, Mason JW, Billingham ME, Daniels JR. Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J. 1981 Oct; 102(4):709-18.
    View in: PubMed
    Score: 0.009
  40. Bristow MR, Billingham ME, Mason JW, Daniels JR. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep. 1978 Jun; 62(6):873-9.
    View in: PubMed
    Score: 0.007
  41. Billingham ME, Bristow MR, Glatstein E, Mason JW, Masek MA, Daniels JR. Adriamycin cardiotoxicity: endomyocardial biopsy evidence of enhancement by irradiation. Am J Surg Pathol. 1977 Mar; 1(1):17-23.
    View in: PubMed
    Score: 0.006
  42. Cohn JN, Bristow MR, Chien KR, Colucci WS, Frazier OH, Leinwand LA, Lorell BH, Moss AJ, Sonnenblick EH, Walsh RA, Mockrin SC, Reinlib L. Report of the National Heart, Lung, and Blood Institute Special Emphasis Panel on Heart Failure Research. Circulation. 1997 Feb 18; 95(4):766-70.
    View in: PubMed
    Score: 0.006
  43. Cleland JG, Bristow MR, Erdmann E, Remme WJ, Swedberg K, Waagstein F. Beta-blocking agents in heart failure. Should they be used and how? Eur Heart J. 1996 Nov; 17(11):1629-39.
    View in: PubMed
    Score: 0.006
  44. Deisher TA, Narita H, Zera P, Ginsburg R, Bristow MR, Billingham ME, Fowler MB, Hoffman BB. Protective effect of clentiazem against epinephrine-induced cardiac injury in rats. J Pharmacol Exp Ther. 1993 Jul; 266(1):262-9.
    View in: PubMed
    Score: 0.005
  45. Lurie KG, Bristow MR, Minobe WA, Masek M, Billingham ME. 6-Hydroxydopamine mediated cardiotoxicity in rabbits. Am J Cardiovasc Pathol. 1988; 2(2):181-91.
    View in: PubMed
    Score: 0.003
  46. Lurie KG, Billingham ME, Masek MA, Ginsburg R, Bristow MR, Harrison D, Reitz BA. Ultrastructural and functional studies on prolonged myocardial preservation in an experimental heart transplant model. J Thorac Cardiovasc Surg. 1982 Jul; 84(1):122-9.
    View in: PubMed
    Score: 0.002
  47. Ginsburg R, Bristow MR, Stinson EB, Harrison DC. Histamine receptors in the human heart. Life Sci. 1980 Jun 30; 26(26):2245-9.
    View in: PubMed
    Score: 0.002
  48. Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep. 1978 Jun; 62(6):865-72.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)